Nalaganje...
Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug
CEP-1347 is a mixed lineage kinase inhibitor tested in a large-scale phase 2/3 clinical trial in early Parkinson’s disease, in which its safety and tolerability, but nevertheless not efficacy, was demonstrated. Here we identify by drug repositioning CEP-1347 as a potential anti-cancer stem cell drug...
Shranjeno v:
| izdano v: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Impact Journals LLC
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5706919/ https://ncbi.nlm.nih.gov/pubmed/29212273 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22033 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|